Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8668351 | Journal of Clinical Lipidology | 2018 | 11 Pages |
Abstract
Patients with LAL-D have high atherogenic risk. It is essential to address the underlying LAL deficiency to restore cholesterol homeostasis in LAL-D patients, as treatment with sebelipase alfa improves atherogenic measures regardless of LLM use and for a sustained period. Sebelipase alfa appears to reduce LDL-C by decreasing the LDL-P number, suggesting improvement in cardiovascular disease risk in LAL-D patients.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Don P. MD, FNLA, Mark MD, Sachin MBBS, MPH, Tyler PhD, Eric MD,